Three 2BCured Researchers to Present at 7th European GRIN Conference
We are thrilled to share that three scientists from the 2BCured network – Dr. Shai Berlin, Dr. Shani Stern, and Dr. Avi Schroeder – have been invited as speakers at GRIN Europe’s upcoming 7th GRIN Conference. This is a meaningful recognition of their innovative efforts to turn GRIN2B research into real-world therapeutic solutions. Their participation underscores the strength of our collaborative ecosystem and the shared commitment to advancing GRIN research. We’re grateful to the organizers for amplifying their work and look forward to sharing reflections after the event.
Dr. Shai Berlin – Technion
Dr. Berlin leads the Berlin Lab at the Technion, exploring the physiology and pathophysiology of NMDA receptors – crucial in understanding GRIN2B-Related Neurodevelopmental Disorder. His team identified GRIN2B mutations that reduce glutamate binding by 1,000–2,000‑fold, the most severe deficits reported to date. Most recently, he secured a patent for a novel gene therapy aimed at treating GRIN2B-Related Disorder. The patent involves use of a recombinant adeno-associated virus (AAV) vector capable of delivering a full-length, healthy GRIN2B gene across the blood-brain barrier to restore proper NMDA receptor function in neurons. His presentation will delve into the related research and therapeutic implications.
Dr. Shani Stern – University of Haifa
As head of the Precision Disease Modeling Lab, Dr. Stern champions cutting-edge 2D and 3D brain organoid platforms to test patient-specific gene and drug therapies. Her innovations include creating mini brains from a simple blood sample taken from children with various neurological disorders including GRIN2B-Related Disorder, that could revolutionize personalized treatments. She will present her latest findings on testing FDA-approved drugs for GRIN2B patients.
Dr. Avi Schroeder – Technion
A tenured Associate Professor of Chemical Engineering, Dr. Schroeder spearheads the Lab for Targeted Drug Delivery and Personalized Medicine. His group is breaking new ground with lipid nanoparticle-based gene therapy delivery systems aimed at targeting neurons affected by GRIN2B mutations. His talk will cover state-of-the-art delivery technologies and therapeutic strategies.
The 7th GRIN Conference is a preeminent gathering of researchers, clinicians, and patient advocates focused on GRIN-Related Neurodevelopmental Disorders. It will be hosted by GRI Italia and held at The Palace Grand Hotel in Varese, Italy from October 17th – 19th. This conference unites families, scientists, and medical professionals for a mix of expert presentations, collaborative discussions, and community-focused events dedicated to advancing care and support for those impacted.
Excitingly, GRIN Europe has extended their early bird registration through August 31st. For more information and to register either for in-person or virtual attendance visit https://grinconferences.org/7th/.
